干眼症新兴治疗方法及未来展望

庞 俊莹, 王 静岚, 陈 奕彤, 龙 昭宇, 付 棋
广州中医药大学佛山临床医学院

摘要


干眼症（Dry Eye Disease，DED）是一种多因素眼表疾病，在全球范围内患病率高。传统治疗方法存在局限性。近年来生物制剂、干细胞疗法、纳米技术、基因疗法及自体血液疗法等成为研究热点。同时，多样化的给药方法、个性化精准化的治疗方案及与3D打印、AI辅助诊断等技术结合的方式，展现出良好前景。本文综述近年来干眼症新兴治疗方法的研究进展，探讨其临床转化潜力及未来发展方向。

关键词


干眼症；免疫疗法；干细胞疗法；纳米技术；基因疗法

全文:

PDF


参考


[1]Huang D, Li Z. Multidimensional immunotherapy for dry eye disease: current status and future directions[J]. Front Ophthalmol (Lausanne). 2024 Nov 1;4:1449283.

[2]中华医学会眼科学分会角膜病学组，中国医师协会眼科医师分会角膜病学组.中国干眼临床诊疗专家共识（2024年）[J].中华眼科杂志，2024，60（12）：968-976.

[3]Ashkenazy N, Karp CL, Wang G, et al. Immunosuppression as a possible risk factor for interferon nonresponse in ocular surface squamous neoplasia[J]. Cornea. 2017. 36:506-10.

[4]Katarzyna PB, Wiktor S, Ewa D, et al. Current treatment of systemic lupus erythematosus: a clinician's perspective[J]. Rheumatol Int. 2023. 43:1395-407.

[5]Grosskreutz CL, Hockey HU, Serra D, et al. Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab[J]. Cornea. 2015 Dec;34(12):1551-6.

[6]Amparo, Francisco, Dastjerdi, et al.Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease[J].JAMA OPHTHALMOLOGY,2013,131(06):715-723.

[7]张传宏，胡淑娴，潘燕婷，等.阿达木单抗治疗非感染性葡萄膜炎研究进展[J].国际眼科杂志，2021，21（09）：1561-1565.

[8]Pflugfelder SC, Stern M, Zhang S, et al. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease[J]. J Ocul Pharmacol Ther. 2017 Jan/Feb;33(1):5-12.

[9]章爽，邵毅，高桂平.抗VEGF药物在眼科学与肿瘤学的应用研究进展[J].国际眼科杂志，2020，20（10）：1760-1763.

[10]Jiang X, Lv H, Qiu W, et al. Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye[J]. Drug Des Devel Ther. 2015 Jun 12;9:3043-50.

[11]Yang X, Zuo X, Zeng H, et al. IFN-γ Facilitates Corneal Epithelial Cell Pyroptosis Through the JAK2/STAT1 Pathway in Dry Eye[J]. Invest Ophthalmol Vis Sci. 2023 Mar 1;64(3):34.

[12]马诚，刘增业.原发性干燥综合征型干眼症综合治疗进展[J].医学理论与实践，2022，35（13）：2197-2200.

[13]Joshi JM, Muttigi MS, Upadhya R, et al. An overview of the current advances in the treatment of inflammatory diseases using mesenchymal stromal cell secretome[J]. Immunopharmacol Immunotoxicology. (2023) 45:497-507.

[14]李琛琛.SPARC修饰的脂肪间充质干细胞对犬干眼症的治疗效果评价[D].西北农林科技大学，2024.

[15]Møller-Hansen M, Larsen AC, Wiencke AK, et al. Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sjögren's syndrome: A randomized clinical trial[J]. Ocul Surf. 2024 Jan;31:1-8.

[16]Guo R, Liang Q, He Y, et al. Mesenchymal Stromal Cells-Derived Extracellular Vesicles Regulate Dendritic Cell Functions in Dry Eye Disease[J]. Cells. 2022 Dec 22;12(1):33.

[17]Jiang H, Xu Z. Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment[J]. Drug Deliv. 2023 Dec;30(1):2204206.

[18]Mishra A, Halder J, Saha I, et al. Biogenic Amino Acid Cross-Linked Hyaluronic Acid Nanoparticles Containing Dexamethasone for the Treatment of Dry Eye Syndrome[J]. AAPS PharmSciTech. 2025 Mar 27;26(4):97.

[19]Schechter BA, Urbieta M, Bacharach J, et al. Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial[J]. Clin Ophthalmol. 2022 Dec 13;16:4145-4151.

[20]Zhao L, Li X, Gao M, et al. M6A Modified miR-31-5p Suppresses M1 Macrophage Polarization and Autoimmune Dry Eye by Targeting P2RX7[J]. Adv Sci (Weinh). 2025 May;12(17):e2415341.

[21]Xie M, Wu Y, Zhang Y, et al. Membrane Fusion-Mediated Loading of Therapeutic siRNA into Exosome for Tissue-Specific Application[J]. Adv Mater. 2024 Aug;36(33):e2403935.

[22]Lin JB, Shen X, Pfeifer CW, et al. Dry eye disease in mice activates adaptive corneal epithelial regeneration distinct from constitutive renewal in homeostasis[J]. Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2204134120.

[23]Zhu X, Xu M, Portal C, et al. Identification of Meibomian gland stem cell populations and mechanisms of aging[J]. bioRxiv [Preprint]. Update in: Nat Commun. 2025 Feb 15;16(1):1663.

[24]Xu C, Lu Z, Luo Y, et al. Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases[J]. Nat Commun. 2018 Oct 5;9(1):4092.

[25]陈多军.自体富血小板血浆治疗中重度干眼病的临床疗效及其安全性[J].临床合理用药杂志，2022，15（18）：160-162.

[26]梁晓彦，杨洁，郭翠欣，等.自体血清联合普拉洛芬治疗白内障人工晶体植入术后干眼症疗效评价[J].中国药业，2024，33（10）：104-107.

[27]史薇，刘亚男，史增友.加减逍遥散方离子导入治疗睑板腺功能障碍所致干眼症50例临床观察[J].河北中医，2017，39（02）：224-227.

[28]Mu J, Ding X, Song Y, et al. ROS-Responsive Microneedle Patches Enable Peri-Lacrimal Gland Therapeutic Administration for Long-Acting Therapy of Sjögren's Syndrome-Related Dry Eye[J]. Adv Sci (Weinh). 2025 Apr;12(16):e2409562.

[29]马宏杰，郑燕林.中医治疗干眼方法研究新进展[J].中华中医药杂志，2018，33（04）：1469-1473.


Refbacks

  • 当前没有refback。